IRIS
SANTONI, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.831
AS - Asia 3.873
EU - Europa 3.856
SA - Sud America 820
Continente sconosciuto - Info sul continente non disponibili 267
AF - Africa 261
OC - Oceania 9
Totale 19.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.652
SG - Singapore 1.338
RU - Federazione Russa 722
VN - Vietnam 708
CN - Cina 662
BR - Brasile 654
IT - Italia 587
UA - Ucraina 477
SE - Svezia 392
IE - Irlanda 389
DE - Germania 370
HK - Hong Kong 367
FR - Francia 210
TR - Turchia 203
FI - Finlandia 188
GB - Regno Unito 168
DK - Danimarca 158
CI - Costa d'Avorio 151
IN - India 141
CA - Canada 108
KR - Corea 104
BD - Bangladesh 91
AR - Argentina 63
NL - Olanda 44
JP - Giappone 42
ID - Indonesia 39
MX - Messico 37
PL - Polonia 37
ZA - Sudafrica 36
IQ - Iraq 30
CO - Colombia 25
MA - Marocco 24
EE - Estonia 23
EC - Ecuador 22
ES - Italia 22
PK - Pakistan 22
BE - Belgio 19
PH - Filippine 19
VE - Venezuela 16
UZ - Uzbekistan 13
EG - Egitto 10
PY - Paraguay 10
SA - Arabia Saudita 10
TN - Tunisia 10
MY - Malesia 9
AT - Austria 8
AZ - Azerbaigian 8
CL - Cile 8
DZ - Algeria 8
IL - Israele 8
LB - Libano 8
PE - Perù 8
AU - Australia 7
BO - Bolivia 7
CZ - Repubblica Ceca 7
KE - Kenya 7
KZ - Kazakistan 7
TT - Trinidad e Tobago 7
DO - Repubblica Dominicana 6
PS - Palestinian Territory 6
EU - Europa 5
JO - Giordania 5
NP - Nepal 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
BY - Bielorussia 4
CH - Svizzera 4
CR - Costa Rica 4
HN - Honduras 4
LT - Lituania 4
SY - Repubblica araba siriana 4
ET - Etiopia 3
GR - Grecia 3
TH - Thailandia 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
GT - Guatemala 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LU - Lussemburgo 2
MU - Mauritius 2
NG - Nigeria 2
NI - Nicaragua 2
OM - Oman 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TW - Taiwan 2
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
CY - Cipro 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
GP - Guadalupe 1
Totale 19.636
Salva come PNG Salva come JPEG
Città #
Ashburn 1.712
Singapore 895
Chandler 857
Fairfield 705
Des Moines 687
Dallas 549
Jacksonville 529
San Jose 441
Dublin 387
Wilmington 381
Hong Kong 362
Council Bluffs 358
Boardman 319
Woodbridge 306
Seattle 274
Houston 260
New York 257
Ho Chi Minh City 228
The Dalles 197
Cambridge 195
Beijing 168
Hanoi 160
Lawrence 159
Princeton 159
San Mateo 153
Abidjan 151
Los Angeles 142
Lauterbourg 140
Ann Arbor 126
Moscow 113
Centro 98
Munich 89
San Diego 79
Helsinki 65
Milan 63
Chicago 61
Pune 59
Hefei 54
São Paulo 49
Santa Clara 48
Columbus 47
Da Nang 47
Orem 47
Vancouver 45
London 43
Turku 43
Washington 41
Turin 39
Buffalo 37
Tokyo 37
Marche 33
Haiphong 31
Warsaw 31
Brooklyn 29
Frankfurt am Main 28
Guangzhou 27
Redmond 26
Miano 24
Atlanta 23
Chennai 22
Falls Church 22
Montreal 22
Shanghai 22
Denver 21
Ancona 20
Norwalk 20
Johannesburg 19
Mexico City 19
Phoenix 19
San Francisco 19
Wuhan 19
Brussels 17
Rio de Janeiro 17
Belo Horizonte 16
Manchester 16
Rome 16
Brasília 15
Poplar 15
Stockholm 15
Jakarta 14
Jiaxing 14
Hải Dương 13
Tashkent 13
Amsterdam 12
Baghdad 12
Can Tho 12
Porto Alegre 12
Seoul 12
Ankara 11
Kilburn 11
Mumbai 11
Guarulhos 10
New Delhi 10
Quận Ba 10
Thái Nguyên 10
Boston 9
Curitiba 9
Dhaka 9
Elk Grove Village 9
Fayetteville 9
Totale 13.316
Salva come PNG Salva come JPEG
Nome #
Metabolic phenotype of bladder cancer 267
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 204
Designing novel immunocombinations in metastatic renal cell carcinoma 204
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 202
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 200
Predicting future cancer burden in the United States by artificial neural networks 200
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 194
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 187
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 186
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 183
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 179
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 175
Exploring the Spectrum of Kidney Ciliopathies 172
HER family receptor expression and prognosis in pancreatic cancer 169
Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients 169
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 169
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 167
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date 165
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy 164
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 163
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 163
Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer 163
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 163
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 161
Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy 161
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 161
An update on investigational therapies that target STAT3 for the treatment of cancer 160
Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States 159
Microbiome and cancers, with focus on genitourinary tumors 158
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 158
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 156
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 156
Metabolic Alterations in Renal and Prostate Cancer 155
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 154
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 153
High CTLA-4 expression correlates with poor prognosis in thymoma patients 153
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 151
Molecular characterization of testicular germ cell tumors using tissue microdissection 150
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 149
Bone targeting agents in patients with metastatic prostate cancer: State of the art 148
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 147
Trattamento del carcinoma del pancreas. Attualità e prospettive 145
Is There a Role for Immunotherapy in Prostate Cancer? 145
Hyponatremia in cancer patients: Time for a new approach 143
Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms 142
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 142
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 142
AR-V7 and prostate cancer: The watershed for treatment selection? 141
Pd-l1 inhibitors for the treatment of prostate cancer 141
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 139
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 138
An overview of emerging immunotargets of genitourinary tumors 137
Risk of hyponatraemia in cancer patients treated with targeted therapies: A systematic review and meta-analysis of clinical trials 136
IMPACT OF VEGF, VEGFR, PDGFR, HIF AND ERCC1 GENE POLYMORPHISMS ON THYMIC MALIGNANCIES OUTCOME 136
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 136
Bladder cancer: molecular determinants of personalized therapy 136
Present and future of personalized medicine in adult genitourinary tumors 135
The identification of immunological biomarkers in kidney cancers 133
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 132
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 131
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 131
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 130
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 130
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 129
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 128
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 126
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 126
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 125
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 125
Healthcare cost of HER2-positive and negative breast tumors in the United States (2012–2035) 124
An update on immunotherapy in uro-oncology 124
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 123
Urinary catheters and biofilm formation 122
Emerging Immunotargets and Immunotherapies in Prostate Cancer 121
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 121
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 120
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 119
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 119
Renal Cell Carcinoma: genomic landscape and clinical implications 119
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 118
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 117
Exploring small extracellular vesicles for precision medicine in prostate cancer 115
Epigenetic modulations and lineage plasticity in advanced prostate cancer 115
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 114
Role of STAT3 pathway in genitourinary tumors 114
Agent-Based Learning Model for the Obesity Paradox in RCC 114
Treating prostate cancer by antibody-drug conjugates 114
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 114
Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. 113
Pazopanib and sunitinib trigger autophagic and non autophagic death of bladder tumor cells. 112
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 112
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 112
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 112
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 112
Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. 111
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 111
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 111
The route to personalized medicine in bladder cancer: where do we stand? 111
Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma 110
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 110
Totale 14.362
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.947
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.947
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.146 0 208 40 24 26 142 33 65 101 118 134 255
2022/20232.865 238 271 148 214 151 879 6 156 584 13 152 53
2023/20241.401 238 34 99 162 203 362 30 41 4 30 17 181
2024/20252.547 322 206 32 16 103 88 240 92 585 239 275 349
2025/20267.123 447 509 475 541 824 466 1.335 735 662 569 160 400
2026/2027478 271 207 0 0 0 0 0 0 0 0 0 0
Totale 19.917